Search Results
Aug 24, 2026, 02:14 ET China Hoy:Embajador de Perú en China: Es una cooperación menos condicionada que la cooperación que hemos recibido de otros países desarrollados
esa cooperación".Youtube : https://youtu.be/D4ukCjQ8s1k?si=KQTpPhhTUVgq4pJ7Web : https://www.chinahoy.com.cn/2018/sp/202608/t20260806_800443639.htmlFB
More news about: China Hoy
Aug 13, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
now enrolling patients.About DAYBREAK (and KSI-501)The DAYBREAK study is a non-inferiority study evaluating parallel investigational arms of KSI-501 and Zenkuda against active comparator aflibercept. Patients randomized to KSI-501 will receive fixed every 8-week dosing with additional
More news about: Kodiak Sciences Inc.
Aug 10, 2026, 16:43 ET Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
durability.In preclinical models, KSI-501 was shown to be a potent inhibitor of both VEGF and IL-6 and to normalize the blood-retinal barrier, opening the possibility that KSI-501 may be a disease-modifying therapy for retinal vascular diseases.About KSI-501KSI-501 is an investigational
More news about: Kodiak Sciences Inc.
Aug 06, 2026, 07:00 ET Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study, with topline data expected in September 2026. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored
More news about: Kodiak Sciences Inc.
Jul 29, 2026, 09:01 ET Knox is First to Operationalize at Scale FedRAMP 20x with Continuous Vulnerability Detection and Reporting
evidence generationPersistent validation of security controlsContinuous security decision recordsKey Security Indicator (KSI) trackingOngoing certification reportingSignificant change managementContinuous evidence readinessTogether, these
More news about: Knox Systems, Inc
Jul 14, 2026, 09:00 ET Commas, the Platform Quietly Powering Billions in Online Sales, Opens to Everyone as AI Pushes Millions to Earn Online
entrepreneurs, including Daymond John, Jeremy Miner, Alex Eubank, and Dan Fleyshman. Commas is backed by Left Lane Capital, Ryan Serhant, Gerard Piqué, and KSI and The Sidemen."AI is already starting to displace people from their jobs, and we're building the place they land," said Yash Daftary, founder
More news about: Commas
May 28, 2026, 18:09 ET Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs: Zenkuda™ (tarcocimab tedromer), KSI-501 and KSI-101.For more information, please visit
More news about: Kodiak Sciences Inc.
May 07, 2026, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
are expected in 3Q 2026.About DAYBREAK (and KSI-501)The DAYBREAK study is a non-inferiority study evaluating parallel investigational arms of KSI-501 and Zenkuda against active comparator aflibercept. Patients randomized to KSI-501 will receive fixed every 8-week dosing with additional
More news about: Kodiak Sciences Inc.
May 06, 2026, 06:01 ET Vermilion Energy Inc. Reports Strong Q1 2026 Operational and Financial Results and Continued Debt Reduction
excellence. Subsequent to quarter-end, Vermilion joined the Rockies LNG consortium to evaluate additional diversification for Montney gas through the Ksi Lisims LNG project. This potential diversification option would complement the 26 mmcf/d currently shipped on the Alliance pipeline to the premium-priced
More news about: Vermilion Energy Inc.
May 01, 2026, 00:23 ET Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
development of KSI-101, KSI-102, KSI-103, Zenkuda, KSI-501, or any other product candidate may occur; the risk that safety, efficacy, and durability data observed in Kodiak's product candidates in current or prior studies may not continue or persist; the risk that preclinical data for KSI-102, KSI-103, the geographic
More news about: Kodiak Sciences Inc.
Mar 31, 2026, 16:45 ET Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
are expected in 3Q 2026.About DAYBREAK (and KSI-501)The DAYBREAK study is a non-inferiority study evaluating parallel investigational arms of KSI-501 and Zenkuda against active comparator aflibercept. Patients randomized to KSI-501 will receive fixed every 8-week dosing with additional
More news about: Kodiak Sciences Inc.
Mar 26, 2026, 06:00 ET Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
expected in Q32026.About DAYBREAK (and KSI-501)The DAYBREAK study is a non-inferiority study evaluating parallel investigational arms of KSI-501 and Zenkuda against active comparator aflibercept. Patients randomized to KSI-501 will receive fixed every 8-week dosing with additional
More news about: Kodiak Sciences Inc.
Feb 06, 2026, 01:24 ET 'Shatak' Teaser Unveils the Untold Story of a Century-Long Journey of the RSS
yoga guru Baba Ramdev.Teaser: https://youtu.be/tRWJxl5Fj5k?si=UdU94BIRqLNMVavQ Shatak: Rashtriya Swayamsevak Sangh ke 100 Varsh is set to release in theatres nationwide on 19 February 2026Photo
More news about: ADA 360 Degrees LLP
Feb 04, 2026, 07:00 ET Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
enrolling, these final results strengthen our confidence in KSI-101's potential to become a safe, first-line unifying therapy for all causes of MESI," said Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences. About KSI-101KSI-101 is a novel, potent and high strength (100 mg/mL)
More news about: Kodiak Sciences Inc.
Feb 02, 2026, 06:59 ET Aluminum Extrusion Market worth $166.65 billion by 2030 - Exclusive Report by MarketsandMarkets™
anodizing or painting. Common tempers like T5 or T6 enhance strength via precipitation hardening at 160-182°C. They balance tensile strength (18-58 ksi) with ductility, though sensitive to cracking if not managed.Popular 6xxx alloy grades are 6061, 6063, and 6005. 6061 is a versatile structural
More news about: MarketsandMarkets
Jan 28, 2026, 09:15 ET Epicore Biosystems Advances Hydration Intelligence with New Scientific Advisors in Heat, Performance, and Proteomics
hydration, stress, and fatigue to shape workforce safety, fitness, and overall health and performance.Dr. Casa, CEO of the Korey Stringer Institute (KSI) at the University of Connecticut and a globally recognized authority on exertional heat illness prevention, brings unparalleled expertise in heat safety,
More news about: Epicore Biosystems, Inc.
Jan 07, 2026, 20:19 ET Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases, targeting the $15 billion anti-VEGF marketplace, with topline data readouts expected in 1Q 2026 and 3Q 2026. KSI-101 is a bispecific protein being explored in two
More news about: Kodiak Sciences Inc.
Dec 18, 2025, 20:26 ET Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
which strengthens our financial position as we execute through important Phase 3 topline readouts for all three of our late-stage clinical assets of KSI-101, KSI-501 and tarcocimab. The transaction was thoughtfully structured, reflecting our disciplined approach to capital formation and our continued focus
More news about: Kodiak Sciences Inc.
Dec 16, 2025, 22:55 ET Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation
More news about: Kodiak Sciences Inc.
Dec 15, 2025, 16:01 ET Kodiak Sciences Announces Proposed Public Offering of Common Stock
discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation
More news about: Kodiak Sciences Inc.
Dec 09, 2025, 08:49 ET Baltimore's Monkey in the Metal Expands Capabilities With KSI Professional Acquisition and New 12,000 Sq. Ft. Facility
landmark projects including Ammoora Restaurant and Maryland Science Center MAKE Exhibit, today announced the successful completion of its acquisition of KSI Professional, a 30-year leader in presentation furniture and professional speaker systems. The real estate and business acquisition, finalized
More news about: Monkey in the Metal
Nov 13, 2025, 16:05 ET Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
https://clinicaltrials.gov/study/NCT06556368). About KSI-101 KSI-101 is a novel, potent and high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are developing KSI-101 for patients with macular edema (retinal fluid) secondary to
More news about: Kodiak Sciences Inc.
Nov 12, 2025, 17:48 ET Kodiak Sciences to Present at Upcoming Investor Conferences
developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases, targeting the $15 billion anti-VEGF marketplace. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular
More news about: Kodiak Sciences Inc.
Nov 12, 2025, 08:00 ET Built by Creators, for Creators: Insta360 Introduces Four New Premium Videography Bundles
https://youtu.be/3ioGGM71c7k?si=CNIJA0mQxJxIN552 About Insta360
More news about: Insta360
Nov 05, 2025, 07:00 ET Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
https://ir.kodiak.com/events-and-presentations/events About KSI-101 KSI-101 is a novel, potent and high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are developing KSI-101 for patients with macular edema (retinal fluid) secondary to
More news about: Kodiak Sciences Inc.